Camrelizumab Combined With Apatinib 、Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
Conditions: Gastroesophageal Junction Adenocarcinoma (Siewert II-III) Interventions: Drug: Camrelizumab+Apatinib+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | China Health | Eloxatin | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Hospitals | Research